Opinion/decision on a Paediatric investigation plan (PIP): Gazyvaro, Obinutuzumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0502/2022

PSUSA/00010130/202502

Human medicines European public assessment report (EPAR): Bemrist Breezhaler, indacaterol,mometasone, Date of authorisation: 30/05/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Selincro, nalmefene, Date of authorisation: 24/02/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 39, Status: Authorised

Minutes of the CHMP written procedure 18-21 August 2025

SPOR and XEVMPD status update webinar, Broadcast, from 8 October 2025, 10:00 (CEST) to 8 October 2025, 12:30 (CEST)

Agenda of the CAT meeting 8-9 October 2025

HMA-EMA joint Network Data Steering Group meeting - 16 September 2025

Public webinar on shortages: putting patients first, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 4 November 2025, 14:00 (CET) to 4 November 2025, 16:00 (CET)